Navigation Links
EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Date:4/22/2008

o develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corpo
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
2. EntreMed Receives Nasdaq Deficiency Notice
3. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
4. EntreMed Announces 2008 Corporate and Clinical Program Priorities
5. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
6. EntreMed to Present at BIO CEO and Investor Conference
7. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
8. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
9. EntreMed Appoints Senior Vice President of Research and Development
10. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
11. Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 Trigemina, Inc., a ... non-narcotic, nasally delivered, analgesic drug products, announced today that ... the position of chief medical officer. Dr. Kori brings ... much of which has been focused in the neuroscience ... add Dr. Kori to our clinical team given his ...
(Date:8/4/2015)...  Blueprint Medicines (NASDAQ: BPMC ), a leader ... genomically defined diseases, today announced that Jeffrey Albers ... at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, ... A live webcast of the event will be available ... website at www.blueprintmedicines.com . An archived replay of ...
(Date:8/4/2015)... ANGELES , Aug. 4, 2015   California ... the recent acquisition of LifeLine Cryogenics, an east coast ... New York tristate area. LifeLine ... and all prepaid contracts will be honored. ... cryogenics services, offering storage of sperm, eggs, embryos, and ...
(Date:8/3/2015)... Aug. 3, 2015  ArroGen Group, an integrated ... Fingerprint Molecular Identification™ (FMID) technology Aug. 2-8 at ... Sacramento, Calif. ... enable law enforcement agents, district attorneys and government ... suspects. By analyzing chemical residues on ...
Breaking Biology Technology:Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3FamilyCord Announces Acquisition of LifeLine Cryogenics 2ArroGen Previews New Fingerprint Molecular Identification Technology 2
... , SEATTLE, July 30 Dendreon Corporation (Nasdaq: DNDN ... a.m. PT; 11:30 a.m. ET to review second quarter 2009 financial results. Access ... Time: 11:30 AM ET /8:30 ... Dial-in: 1-877-548-7903 (domestic) or +1-719-325-4873 (international), ...
... LAUSANNE, Switzerland and MEDFORD, Massachussets, ... biopharmaceutical group,of companies with a focus on the ... and MSM Protein Technologies (MSM), a human,antibody drug ... membrane proteins, announce the signature of an exclusive,agreement ...
... , , PLEASANTON, Calif., ... (Nasdaq: THOR ), a world leader in device-based ... hearts, and HeartWare International, Inc. (Nasdaq: HTWR ; ... announced today that the United States Federal Trade Commission ("FTC") ...
Cached Biology Technology:Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 3Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 4U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International 2U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International 3U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International 4
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale Konferenz ... BGI veranstaltet und findet vom 22. bis 25. ... , statt. Die Konferenz feiert ... Start 2006 ist die ICG weltweit zu einem ... Sie ist eines der dynamischsten, enthusiastischsten und angenehmsten ...
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... $5 million National Science Foundation (NSF) grant to upgrade ... Owens Valley Solar Array (OVSA) http://www.ovsa.njit.edu/ ... is expected to help scientists better understand the nature ... the military. "Space weather incidents such as ...
... What:,Based on what we know about smoking, diet, ... estimate we could prevent approximately half of all ... Association for Cancer Research will host its Ninth ... Research at the Pennsylvania Convention Center, located in ...
... Bad Hofgastein, 6 October 2010 -- European patients are in ... medically assisted reproduction (MAR) treatment, experts from the European Society ... European Health Forum Gastein (EHFG). The EHFG is ... EU. This year it has attracted about 600 decision-makers from ...
Cached Biology News:$5 million NSF grant will upgrade and expand NJIT radio telescope array 2$5 million NSF grant will upgrade and expand NJIT radio telescope array 3Reproductive health: Checkerboard of infertility treatment in Europe 2Reproductive health: Checkerboard of infertility treatment in Europe 3
...
Chicken polyclonal to ADI1 ( Abpromise for all tested applications). Antigen: Full length native protein (purified), corresponding to amino acids 1-179 of Human ADI1. Entrez GeneID: 55256 ...
ABI Plant AFLP Kits • EcoRI-ACA AFLP Amplification Primers...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Biology Products: